Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Changsong Qi(Peking University), Chang Liu(Peking University), Jifang Gong(Peking University), Dan Liu(Peking University), Xicheng Wang(Peking University), Panpan Zhang(Peking University), Yanru Qin(First Affiliated Hospital of Zhengzhou University), Sai Ge(Peking University), Miao Zhang(Peking University), Zhi Peng(Peking University), Jun Zhou(Peking University), Zhihao Lü(Peking University), Ming Lu(Peking University), Yanshuo Cao(Peking University), Jiajia Yuan(Peking University), Yakun Wang(Peking University), Zhenghang Wang(Peking University), Ran Xue(Peking University), Xiaohui Peng(Regend Therapeutics (China)), Yumeng Wang(Peking University), Daijing Yuan(Regend Therapeutics (China)), Jian Li(Peking University), Xiaotian Zhang(Peking University), Lin Shen(Peking University)
Cited by 170
Abstract
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee, Bianca Santomasso, Frederick L. Locke et al.|Biology of Blood and Marrow Transplantation|2018|3.4k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al.|New England Journal of Medicine|2021|1.5k